Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?

Miljkovic, Milica; Dragos, Vita Setrajcic; Gasljevic, Gorana; Novakovic, Srdjan; Boltezar, Lucka; Novakovic, Barbara Jezersek

doi:10.2478/raon-2025-0028

References

Tilly H, da Silva GM, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26: 116-25. doi: 10.1093/annonc/mdv304
Open DOI Search in Google Scholar Back to article
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (2025). B-cell lymphoma (version 1.2025) [Internet]. [cited 2025 Feb 15]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
Search in Google Scholar Back to article
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36: 1703-19. doi: 10.1038/s41375-022-01613-1
Open DOI Search in Google Scholar Back to article
Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma 2019; 3: 10. doi: 10.21037/aol.2019.09.01
Open DOI Search in Google Scholar Back to article
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800-8. doi: 10.1182/blood-2017-03-769620
Open DOI Search in Google Scholar Back to article
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med 1993; 329: 987-94. doi: 10.1056/NEJM199309303291402
Open DOI Search in Google Scholar Back to article
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et. al. International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-80. doi: 10.1200/JCO.2009.26.2493
Open DOI Search in Google Scholar Back to article
Shimikus G, Nonaka T. Molecular classification and therapeutics in diffuse large B-cell lymphoma. Front Mol Biosci 2023; 10: 1124360. doi: 10.3389/fmolb.2023.1124360
Open DOI Search in Google Scholar Back to article
Weber T, Schmitz R. Molecular subgroups of diffuse large b cell lymphoma: biology and implications for clinical practice. Curr Oncol Rep 2022; 24: 1321. doi: 10.1007/s11912-021-01155-2
Open DOI Search in Google Scholar Back to article
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11. doi: 10.1038/35000501
Open DOI Search in Google Scholar Back to article
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47. doi: 10.1056/NEJMoa012914
Open DOI Search in Google Scholar Back to article
López AB, Villambrosía GS, Francisco M, Malatxeberria S, Sáez A, Montalban C, et al. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget 2016; 7: 18036-49. doi: 10.18632/oncotarget.7495
Open DOI Search in Google Scholar Back to article
Hans CHP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82. doi: 10.1182/blood-2003-05-1545
Open DOI Search in Google Scholar Back to article
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffusse large B-cell lymphoma. N Engl J Med 2018; 378: 1396-1407. doi: 10.1056/NEJMoa1801445
Open DOI Search in Google Scholar Back to article
Chapuy B, Stewart CH, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Med 2018; 24: 67990. doi: 10.1038/s41591-018-0016-8
Open DOI Search in Google Scholar Back to article
Lacy SE, Barrans SHL, Beer PHA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 2020; 135: 1759-71. doi: 10.1182/blood.2019003535
Open DOI Search in Google Scholar Back to article
Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic classification tool for genetic subtypes of diffuse large b cell lymphoma with therapeutic implications. Cancer Cell 2020; 37: 551-68.e14. doi: 10.1016/j.ccell.2020.03.015
Open DOI Search in Google Scholar Back to article
Boltežar L, Kloboves Prevodnik V, Pohar Perme M, Gašljević G, Jezeršek Novaković B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903-12
Search in Google Scholar Back to article
Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov 2024; 14: 49-65. doi: 10.1158/2159-8290.CD-23-0467
Open DOI Search in Google Scholar Back to article
Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res 2016; 25: 1692-706. doi: 10.1177/0962280213497434
Open DOI Search in Google Scholar Back to article
Austin PC, Harrell Jr FE, Klaveren D. Graphical calibration curves and the integrated calibration index (ICI) for survival models. Stat Med 2020; 39: 2714-42. doi: 10.1002/sim.8570
Open DOI Search in Google Scholar Back to article
McLernon DJ, Giardiello D, Calster BV, Wynants L, Geloven N, Smeden M, et al. Assessing performance and clinical usefulness in prediction models with survival outcomes: Practical Guidance for Cox Proportional Hazards Models. Ann Intern Med 2023; 176: 105-14. doi: 10.7326/M22-0844
Open DOI Search in Google Scholar Back to article
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86. doi: 10.1200/JCO.2006.09.2403
Open DOI Search in Google Scholar Back to article
Crotty R, Hu K, Stevenson K, Maggie Y, Pontius MY, Sohani AR, et al. Simultaneous identification of cell of origin, translocations, and hotspot mutations in diffuse large B-cell lymphoma using a single RNA-sequencing assay. Am J Clin Pathol 2021; 155: 748-54. doi: 10.1093/ajcp/aqaa185
Open DOI Search in Google Scholar Back to article
Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015; 33: 2848-56. doi: 10.1200/JCO.2014.60.2383
Open DOI Search in Google Scholar Back to article
Zhang MCH, Tian SH, Fu D, Wang L, Cheng SH, MeiYi H, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell 2023; 41: 1705-16.e5. doi: 10.1016/j.ccell.2023.09.004
Open DOI Search in Google Scholar Back to article
Baliko A, Szakacs Z, Kajtar B, Ritter Z, Gyenesei A, Farkas N, et al. Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers. Front Oncol 2023; 3: 1224733. doi: 10.3389/fonc.2023.1224733
Open DOI Search in Google Scholar Back to article

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?

References

Paradigm

My account